Brian L. Egleston

Fox Chase Cancer Center

Papers

2

Total Citations

303

H-Index

2

About

Brian L. Egleston is a biostatistician whose research bridges quantitative methodology and clinical urologic oncology, with a particular focus on improving decision-making for patients with kidney and prostate cancers. His major contributions include advancing the use of the R.E.N.A.L. nephrometry scoring system to objectively guide treatment choices for renal masses—a framework that has garnered over 160 citations and become a standard tool for urologists weighing surgery versus surveillance. Egleston also conducted pivotal population-based analyses of prostate cancer care, revealing how the rapid adoption of robotic surgery has centralized radical prostatectomies at specialized centers, often increasing travel burdens for patients. His work on these trends, cited over 140 times, highlights disparities in access to advanced urologic cancer care. Through rigorous observational studies and statistical modeling, Egleston has helped quantify how technological shifts in oncology affect real-world patient outcomes and healthcare equity. His research is essential reading for clinicians and health services researchers seeking evidence-based insights into the evolving landscape of cancer treatment delivery.

Research Focus

Key Achievements

2
H-Index
2
Papers
303
Total Citations
152
Avg Citations/Paper
🏆 Most Cited Paper
Utility of the R.E.N.A.L. Nephrometry Scoring System in Objectifying Treatment Decision-making of the Enhancing Renal Mass
163 citations · 2011
📈 Most Prolific Year: 2011 (2 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Fox Chase Cancer Center

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago